The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

Journal of Neuroimmunology

Volumn 277, Issue 1-2, 2014, Pages 153-159

  Burman, Joachim ^a,b   Svensson, Emma ^a   Fransson, Moa ^a   Loskog, Angelica S I ^a   Zetterberg, Henrik ^c,d   Raininko, Raili ^a   Svenningsson, Anders ^e   Fagius, Jan ^a,b   Mangsbo, Sara M ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebrospinal fluid; Cytokines; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

BETA INTERFERON; CD40 LIGAND; CXCL1 CHEMOKINE; CYTOKINE; GADOLINIUM; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; MACROPHAGE DERIVED CHEMOKINE; MITOXANTRONE; NATALIZUMAB; RANTES;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; TH1 CELL; TH17 CELL; TH2 CELL; ADOLESCENT; COMPLICATION; HELPER CELL; INFLAMMATION; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; T-LYMPHOCYTES, HELPER-INDUCER; YOUNG ADULT;

EID: 84918796182     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.10.005     Document Type: Article

References (48)

1. Abrahamsson S.V., Angelini D.F., Dubinsky A.N., Morel E., Oh U., Jones J.L., Carassiti D., Reynolds R., Salvetti M., Calabresi P.A., Coles A.J., Battistini L., Martin R., Burt R.K., Muraro P.A. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 2013, 136:2888-2903.
2. Bielekova B., Komori M., Xu Q., Reich D.S., Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS ONE 2012, 7:e48370.
3. Breij E.C., Brink B.P., Veerhuis R., Van Den Berg C., Vloet R., Yan R., Dijkstra C.D., Van Der Valk P., Bo L. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63:16-25.
4. Bromley S.K., Mempel T.R., Luster A.D. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. 2008, 9:970-980.
5. Burman J., Fransson M., Totterman T.H., Fagius J., Mangsbo S.M., Loskog A.S. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. Immunology 2013, 140:211-219.
6. Burman J., Zetterberg H., Fransson M., Loskog A.S., Raininko R., Fagius J. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol. Scand. 2014, 130:81-89.
7. Charcot J. Histologie de la sclérose en plaques 1868, Gaz Hop, Paris.
8. Columba-Cabezas S., Serafini B., Ambrosini E., Sanchez M., Penna G., Adorini L., Aloisi F. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J. Neuroimmunol. 2002, 130:10-21.
9. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782.
10. Consortium I.M.S.G., Beecham A.H., Patsopoulos N.A., Xifara D.K., Davis M.F., Kemppinen A., Cotsapas C., Shah T.S., Spencer C., Booth D., Goris A., Oturai A., Saarela J., Fontaine B., Hemmer B., Martin C., Zipp F., D'alfonso S., Martinelli-Boneschi F., Taylor B., Harbo H.F., Kockum I., Hillert J., Olsson T., Ban M., Oksenberg J.R., Hintzen R., Barcellos L.F., Wellcome Trust Case Control C., International I.B.D.G.C., Agliardi C., Alfredsson L., Alizadeh M., Anderson C., Andrews R., Sondergaard H.B., Baker A., Band G., Baranzini S.E., Barizzone N., Barrett J., Bellenguez C., Bergamaschi L., Bernardinelli L., Berthele A., Biberacher V., Binder T.M., Blackburn H., Bomfim I.L., Brambilla P., Broadley S., Brochet B., Brundin L., Buck D., Butzkueven H., Caillier S.J., Camu W., Carpentier W., Cavalla P., Celius E.G., Coman I., Comi G., Corrado L., Cosemans L., Cournu-Rebeix I., Cree B.A., Cusi D., damotte V., Defer G., Delgado S.R., Deloukas P., Di Sapio A., Dilthey A.T., Donnelly P., Dubois B., Duddy M., Edkins S., Elovaara I., Esposito F., Evangelou N., Fiddes B., Field J., Franke A., Freeman C., Frohlich I.Y., Galimberti D., Gieger C., Gourraud P.A., Graetz C., Graham A., Grummel V., Guaschino C., Hadjixenofontos A., Hakonarson H., Halfpenny C., Hall G., Hall P., Hamsten A., Harley J., Harrower T., et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 2013, 45:1353-1360.
11. Crome S.Q., Wang A.Y., Levings M.K. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin. Exp. Immunol. 2010, 159:109-119.
12. Darlington P.J., Touil T., Doucet J.S., Gaucher D., Zeidan J., Gauchat D., Corsini R., Kim H.J., Duddy M., Jalili F., Arbour N., Kebir H., Chen J., Arnold D.L., Bowman M., Antel J., Prat A., Freedman M.S., Atkins H., Sekaly R., Cheynier R., Bar-Or A. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann. Neurol. 2013, 73:341-354.
13. Fitzgerald D.C., Ciric B., Touil T., Harle H., Grammatikopolou J., Das Sarma J., Gran B., Zhang G.X., Rostami A. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179:3268-3275.
14. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
15. Galimberti D., Fenoglio C., Comi C., Scalabrini D., De Riz M., Leone M., Venturelli E., Cortini F., Piola M., Monaco F., Bresolin N., Scarpini E. MDC/CCL22 intrathecal levels in patients with multiple sclerosis. Mult. Scler. 2008, 14:547-549.
16. Gerritse K., Laman J.D., Noelle R.J., Aruffo A., Ledbetter J.A., Boersma W.J., Claassen E. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2499-2504.
17. Goules A., Tzioufas A.G., Manousakis M.N., Kirou K.A., Crow M.K., Routsias J.G. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J. Autoimmun. 2006, 26:165-171.
18. Havrdová E., Belova A., Goloborodko A., Tisserant A., Jones I., Garren H., Johns D. Positive Proof of Concept of AIN457, An Antibody Against Interleukin-17A, In Relapsing-Remitting Multiple Sclerosis 2012, ECTRIMS, Lyons.
19. Hochmeister S., Grundtner R., Bauer J., Engelhardt B., Lyck R., Gordon G., Korosec T., Kutzelnigg A., Berger J.J., Bradl M., Bittner R.E., Lassmann H. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2006, 65:855-865.
20. Kato K., Santana-Sahagun E., Rassenti L.Z., Weisman M.H., Tamura N., Kobayashi S., Hashimoto H., Kipps T.J. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. 1999, 104:947-955.
21. Khademi M., Kockum I., Andersson M.L., Iacobaeus E., Brundin L., Sellebjerg F., Hillert J., Piehl F., Olsson T. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult. Scler. 2011, 17:335-343.
22. Leppert I.R., Narayanan S., Araujo D., Giacomini P.S., Lapierre Y., Arnold D.L., Pike G.B. Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don't. J. Neurol. 2014, 261:809-816.
23. Link H., Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest. 1977, 37:397-401.
24. Lublin F., Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
25. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
26. Mahad D.J., Howell S.J., Woodroofe M.N. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2002, 72:498-502.
27. Mahad D., Callahan M.K., Williams K.A., Ubogu E.E., Kivisakk P., Tucky B., Kidd G., Kingsbury G.A., Chang A., Fox R.J., Mack M., Sniderman M.B., Ravid R., Staugaitis S.M., Stins M.F., Ransohoff R.M. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 2006, 129:212-223.
28. Mascanfroni I.D., Yeste A., Vieira S.M., Burns E.J., Patel B., Sloma I., Wu Y., Mayo L., Ben-Hamo R., Efroni S., Kuchroo V.K., Robson S.C., Quintana F.J. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat. Immunol. 2013, 14:1054-1063.
29. Matsushita T., Tateishi T., Isobe N., Yonekawa T., Yamasaki R., Matsuse D., Murai H., Kira J. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS ONE 2013, 8:e61835.
30. Matzinger P., Kamala T. Tissue-based class control: the other side of tolerance. Nat. Rev. Immunol. 2011, 11:221-230.
31. McManus C., Berman J., Brett F., Staunton H., Farrell M., Brosnan C. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J. Neuroimmunol. 1998, 86:20-29.
32. Meinl E., Krumbholz M., Derfuss T., Junker A., Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J. Neurol. Sci. 2008, 274:42-44.
33. Mellergard J., Edstrom M., Vrethem M., Ernerudh J., Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult. Scler. 2010, 16:208-217.
34. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
35. Nolan J.P., Mandy F.F. Suspension array technology: new tools for gene and protein analysis. Cell. Mol. Biol. (Noisy-le-grand) 2001, 47:1241-1256.
36. Omari K.M., Lutz S.E., Santambrogio L., Lira S.A., Raine C.S. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1. Am. J. Pathol. 2009, 174:164-176.
37. Pamukcu B., Lip G.Y., Snezhitskiy V., Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann. Med. 2011, 43:331-340.
38. Peters A.L., Stunz L.L., Bishop G.A. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 2009, 21:293-300.
39. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
40. Rentzos M., Cambouri C., Rombos A., Nikolaou C., Anagnostouli M., Tsoutsou A., Dimitrakopoulos A., Triantafyllou N., Vassilopoulos D. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J. Neurol. Sci. 2006, 241:25-29.
41. Segal B.M. Th17 cells in autoimmune demyelinating disease. Semin. Immunopathol. 2010, 32:71-77.
42. Sellebjerg F., Bornsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L., Sorensen P.S. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010.
43. Skuljec J., Sun H., Pul R., Benardais K., Ragancokova D., Moharregh-Khiabani D., Kotsiari A., Trebst C., Stangel M. CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell. Immunol. 2011, 270:164-171.
44. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., Ransohoff R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 1999, 103:807-815.
45. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
46. Sweeney C.M., Lonergan R., Basdeo S.A., Kinsella K., Dungan L.S., Higgins S.C., Kelly P.J., Costelloe L., Tubridy N., Mills K.H., Fletcher J.M. IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun. 2011, 25:1170-1181.
47. Szczucinski A., Losy J. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis. Neuroimmunomodulation 2011, 18:67-72.
48. Vagesjo E., Christoffersson G., Walden T.B., Carlsson P.O., Essand M., Korsgren O., Phillipson M. Immunological shielding by induced recruitment of regulatory T lymphocytes delays rejection of islets transplanted to muscle. Cell Transplant. 2014, (Epub ahead of print).